Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010;33:1395–1402

Because of a typographical error in the erratum previously published for the article listed above, three of the study names in Fig. 1 were incorrect. In Fig. 1,A, “UKMD” should read “BMD.” In Fig. 1 B, “USP” should read “PHS” and “BDS” should read “BMD.” These errors do not affect the data. The online version reflects these changes.

Figure 1
Figure 1. Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. A: Effect of aspirin on CHD events. Tests for heterogeneity: χ2 = 8.71, P = 0.367, I2 = 8.2%. B: Effect of aspirin on risk of stroke in patients with diabetes. Tests for heterogeneity: χ2 = 11.0, P = 0.20, I2 = 27.2%. BMD, British Medical Doctors; CI, confidence interval; ETDRS, Early Treatment of Diabetic Retinopathy Study; HOT, Hypertension Optimal Treatment; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; PHS, Physicians' Health Study; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial; and WHS, Women's Health Study.
View largeDownload slide

Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. A: Effect of aspirin on CHD events. Tests for heterogeneity: χ2 = 8.71, P = 0.367, I2 = 8.2%. B: Effect of aspirin on risk of stroke in patients with diabetes. Tests for heterogeneity: χ2 = 11.0, P = 0.20, I2 = 27.2%. BMD, British Medical Doctors; CI, confidence interval; ETDRS, Early Treatment of Diabetic Retinopathy Study; HOT, Hypertension Optimal Treatment; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; PHS, Physicians' Health Study; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial; and WHS, Women's Health Study.

Figure 1
Figure 1. Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. A: Effect of aspirin on CHD events. Tests for heterogeneity: χ2 = 8.71, P = 0.367, I2 = 8.2%. B: Effect of aspirin on risk of stroke in patients with diabetes. Tests for heterogeneity: χ2 = 11.0, P = 0.20, I2 = 27.2%. BMD, British Medical Doctors; CI, confidence interval; ETDRS, Early Treatment of Diabetic Retinopathy Study; HOT, Hypertension Optimal Treatment; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; PHS, Physicians' Health Study; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial; and WHS, Women's Health Study.
View largeDownload slide

Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. A: Effect of aspirin on CHD events. Tests for heterogeneity: χ2 = 8.71, P = 0.367, I2 = 8.2%. B: Effect of aspirin on risk of stroke in patients with diabetes. Tests for heterogeneity: χ2 = 11.0, P = 0.20, I2 = 27.2%. BMD, British Medical Doctors; CI, confidence interval; ETDRS, Early Treatment of Diabetic Retinopathy Study; HOT, Hypertension Optimal Treatment; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; PHS, Physicians' Health Study; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial; and WHS, Women's Health Study.

Close modal
View Original Article
© 2011 by the American Diabetes Association.
2011
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.